vandetanib + docetaxel + prednisolone

This is a **combination regimen** consisting of vandetanib, docetaxel, and prednisolone, studied primarily in the context of metastatic hormone-refractory (castration-resistant) prostate cancer. Vandetanib is a small-molecule oral tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) signaling, thereby inhibiting angiogenesis and tumor cell proliferation. Docetaxel is a chemotherapy agent that stabilizes microtubules and inhibits cell division. Prednisolone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. The combination was evaluated in Phase II clinical trials, but did not show benefit over placebo plus docetaxel/prednisolone in this indication[1][3].